Innovent Biologics, Inc. (IVBXF)
OTCMKTS
· Delayed Price · Currency is USD
5.15
0.00 (0.00%)
Mar 7, 2025, 3:00 PM EST
Innovent Biologics Revenue
Innovent Biologics had revenue of 3.95B CNY in the half year ending June 30, 2024, with 76.47% growth. This brings the company's revenue in the last twelve months to 7.46B, up 48.59% year-over-year. In the year 2023, Innovent Biologics had annual revenue of 6.21B with 36.21% growth.
Revenue (ttm)
7.46B CNY
Revenue Growth
+48.59%
P/S Ratio
n/a
Revenue / Employee
1.53M CNY
Employees
4,872
Market Cap
8.20B USD
Revenue Chart
* This company reports financials in CNY.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo Inc. | 1.79B |
SS Innovations International | 16.04M |
Veradigm | 1.53B |
Elite Pharmaceuticals | 70.00M |
Glass House Brands | 188.29M |
Northwest Biotherapeutics | 1.60M |
Silence Therapeutics | 43.26M |
BioStem Technologies | 210.49M |
Innovent Biologics News
- 10 days ago - Head-to-Head Against Pembrolizumab: Innovent Announces First Patient Dosed in the First Pivotal Study of IBI363 (PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Melanoma - PRNewsWire
- 17 days ago - NMPA Accepts NDA and Grants Priority Review Designation to Innovent's Ipilimumab Injection, China's First Domestic CTLA-4 Inhibitor, in Combination with Sintilimab as Neoadjuvant Treatment for Colon Cancer - PRNewsWire
- 24 days ago - Innovent Receives Second Fast Track Designation from the U.S. FDA for IBI363 (PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Squamous Non-Small Cell Lung Cancer - PRNewsWire
- 7 weeks ago - Innovent Biologics Inc (IVBIY) Announces NMPA Approval of Limertinib for Lung Cancer Treatment - GuruFocus
- 7 weeks ago - Innovent Biologics Inc (IVBIY) Unveils Strategic Growth Plans at J.P. Morgan Healthcare Conference - GuruFocus
- 7 weeks ago - Innovent and ASK Pharm Jointly Announce NMPA Approval of Limertinib, a Third-generation EGFR TKI for the Treatment of Lung Cancer - PRNewsWire
- 7 weeks ago - Innovent Presents at the 43rd Annual J.P. Morgan Healthcare Conference - PRNewsWire
- 7 weeks ago - Innovent Biologics Inc (IVBIY) Secures Breakthrough Therapy Designation for IBI343 in Advanced ... - GuruFocus